Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion ($17.2 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of ...

Mar. 5, 2025 — A new seismic study of Singapore could guide urban growth and renewable energy development in the coastal city nation, where 5.6 million residents ... World's Oldest Impact Crater ...

Geology is broadly the study of the Earth and other planets, moons, and smaller planetary bodies. Fields of geology range from the initial formation and differentiation of the Earth to modern ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...